Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia A Randomized Clinical Trial
- Menichetti F.
- Popoli P.
- Puopolo M.
- Alegiani S. S.
- Tiseo G.
- Bartoloni A.
- De Socio G. V.
- Luchi S.
- Blanc P.
- Puoti M.
- Toschi E.
- Massari M.
- Palmisano L.
- Marano G.
- Chiamenti M.
- Martinelli L.
- Franchi S.
- Pallotto C.
- Suardi L. R.
- Pasqua B. L.
- Merli M.
- Fabiani P.
- Bertolucci L.
- Borchi B.
- Modica S.
- Moneta S.
- Marchetti G.
- d'Arminio Monforte A.
- Stoppini L.
- Ferracchiato N.
- Piconi S.
- Fabbri C.
- Beccastrini E.
- Saccardi R.
- Giacometti A.
- Esperti S.
- Pierotti P.
- Bernini L.
- Bianco C.
- Benedetti S.
- Lanzi A.
- Bonfanti P.
- Massari M.
- Sani S.
- Saracino A.
- Castagna A.
- Trabace L.
- Lanza M.
- Focosi D.
- Mazzoni A.
- Pistello M.
- Falcone M.
- Locatelli F.
- Ippolito G.
- Magrini N.
- Bernardini R.
- Brusaferro S.
- De Angelis V.
- Perotti C.
- Remuzzi G.
- De Silvestro G.
- Costantini M.
- Bocchino M.
- De Donno G.
DOIAbstract
IMPORTANCE Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia. OBJECTIVE To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen-to-fraction of inspired oxygen (PaO2/FiO2) ratio between 350 and 200 ...
Add to ORKG